Oxford BioDynamics ( (GB:OBD) ) has provided an update.
Oxford BioDynamics Plc announced a transaction involving its CFO, Paul Stockdale, who transferred 791,176 ordinary shares into his ISA through a sale and repurchase process. This transaction, conducted on the London Stock Exchange, leaves Stockdale with a beneficial interest in 3,077,919 shares, representing 0.16% of the company’s issued share capital. This move is part of routine financial management and does not indicate any significant change in company operations or strategy.
More about Oxford BioDynamics
Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision clinical diagnostic tests for life-changing diseases. The company offers two main products: the EpiSwitch® PSE (Prostate Screening Test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test), which enhance predictive accuracy for prostate cancer and immuno-oncology treatments, respectively. Their proprietary 3D genomic biomarker platform, EpiSwitch®, supports the diagnosis and treatment response evaluation across various medical fields. The company operates from its headquarters in Oxford, UK, with additional facilities in Maryland, USA, and Penang, Malaysia.
YTD Price Performance: -68.33%
Average Trading Volume: 20,827,288
Technical Sentiment Signal: Buy
Current Market Cap: £9.3M
Find detailed analytics on OBD stock on TipRanks’ Stock Analysis page.